[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-639338-105":59,"doc-detail-639338-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","psychotic-depression-ii-trial-olanzapine-exposure-relapse-and-brain-structure-findings","Psychotic Depression II Trial Olanzapine Exposure Relapse and Brain Structure Findings","","Department of Psychiatry affiliation and publication metadata frame a preprint dated August 22, 2023, later published in Molecular Psychiatry. The study evaluates whether olanzapine exposure relates to relapse and changes in brain structure in major depressive disorder with psychotic features. Data from the STOP-PD II randomized placebo-controlled trial were analyzed using olanzapine steady state concentration from sparsely sampled levels, with relapse and cortical thickness as outcomes. Significant associations linked dosage and steady state concentration to left and right cortical thickness, but effects were not dose-dependent within the therapeutic range, with further research needed.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/psychotic-depression-ii-trial-olanzapine-exposure-relapse-and-brain-structure-findings/639338/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/psychotic-depression-ii-trial-olanzapine-exposure-relapse-and-brain-structure-findings/639338.png","ImageObject",300,407,{"name":92,"@type":93},"Rainbow Cat","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-09","2026-10-22",true,{"@type":102,"interactionType":103,"userInteractionCount":81},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What clinical question did the study address regarding olanzapine?","Question",{"text":112,"@type":113},"The study examined whether olanzapine exposure is associated with relapse and with changes in brain structure in patients with major depressive disorder with psychotic features.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What trial data were analyzed in STOP-PD II?",{"text":117,"@type":113},"Analyses used data from the Study of the Pharmacotherapy of Psychotic Depression II, a randomized placebo-controlled trial involving patients who reached remission on sertraline and olanzapine and were then randomized to continue sertraline plus olanzapine or switch to placebo for 36 weeks.",{"name":119,"@type":110,"acceptedAnswer":120},"Were associations between olanzapine exposure and outcomes still significant for all patients?",{"text":121,"@type":113},"Associations related to relapse or cortical thickness were no longer significant when analysis was restricted to participants treated with olanzapine, and the findings suggest effects within the therapeutic range did not depend on dosage or steady state concentration.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},639338,1792703112,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":81,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":129,"read_time":143,"preview_page_count":4},962090769181,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Department of Psychiatry, University of Toronto [https://orcid.org/0000-0002-0303-6450](https://orcid.org/0000-0002-0303-6450)  \nDepartment of Psychiatry, University of Toronto [https://orcid.org/0000-0003-0156-0395](https://orcid.org/0000-0003-0156-0395)  \nWeill Cornell Medical College [https://orcid.org/0000-0001-5677-7001](https://orcid.org/0000-0001-5677-7001)  \nUniversity of Massachusetts Medical School  \nUniversity of Pittsburgh School of Medicine  \nAugust 22nd, 2023  \n [https://doi.org/10.21203/rs.3.rs-3254016/v1](https://doi.org/10.21203/rs.3.rs-3254016/v1)  \n 􀁱 􀅏 This work is licensed under a Creative Commons Attribution 4.0 International License.  \nRead Full License  \n Helena K. Kim has no ¦ nancial relationships with commercial interests. Aristotle N. Voineskos receives funding from the National Institute of Mental Health (NIMH), Canadian Institutes of Health Research, Canada Foundation for Innovation, Centre for Addiction and Mental Health (CAMH) Foundation, and the University of Toronto. Nicholas H. Neufeld receives grant support from the Canadian  \nInstitutes of Health Research, Physicians’ Services Incorporated Foundation, and the University of Toronto. George S. Alexopoulos has served on an advisory board of Otsuka and has been on the speakers bureau of Otsuka. Kathleen S. Bingham receives grant support from the University of Toronto. Alastair J. Flint has received grant support from the US National Institutes of Health, the Patient-Centered Outcomes Research Institute, the Canadian Institutes of Health Research, Brain Canada, the Ontario Brain Institute, and Alzheimer’s Association. Patricia Marino has no ¦ nancial relationships with commercial interests. Anthony J. Rothchild has received grant or research support from Allergan, Janssen, the National Institute of Mental Health, Takeda, Eli-Lilly (medications for a NIH-funded clinical trial), P¦zer (medications for a NIH-funded clinical trial), and the Irving S. and Betty Brud nick Endowed Chair in Psychiatry; is a consultant to Alkermes, GlaxoSmith Kline, Sage Therapeutics, and Sano¦-Aventis; and has received royalties for the Rothschild Scale for Antidepressant Tachyphylaxis; Clinical Manual for the Diagnosis and Treatment of Psychotic Depression, American Psychiatric Press, 2009; The Evidence-Based Guide to Antipsychotic Medications, American Psychiatric Press, 2010; The Evidence-Based Guide to Antidepressant Medications, American Psychiatric Press, 2012; and UpToDate. Ellen M. Whyte receives grant support from the NIMH and Health Resources and Services Administration. Benoit H. Mulsant has received research funding from Brain Canada, the CAMH Foundation, the Canadian Institutes of Health Research, and the US National Institutes of Health (NIH); research support from Bristol-Myers Squibb (medications for an NIH-funded clinical trial), Eli-Lilly (medications for an NIH-funded clinical trial), P¦zer (medications for an NIH-funded clinical trial), Capital Solution Design LLC (software used in a study funded by CAMH Foundation), and HAPPYneuron (software used in a study funded by Brain Canada) .  \n A version of this preprint was published at Molecular Psychiatry on March 19th, 2024. See the published version at [https://doi.org/10.1038/s41380-024-02523-7](https://doi.org/10.1038/s41380-024-02523-7) .  \nSome data suggest that antipsychotics may adversely affect brain structure. We examined the relationship among olanzapine exposure, relapse, and changes in brain structure in patients with major depressive disorder with psychotic features. We analyzed data from the Study of the Ph armacotherapy of Psychotic Depression II trial (STOP-PD II), a randomized, placebo-controlled trial in patients with psychotic depression who attained remission on sertraline and o lanzapine and were randomized to continue sertraline plus o lanzapine or placebo for 36 weeks. Olanzapine steady state concentration (SSC) were calculated based on sparsely-sampled levels. Rates of relapse and","cbCaiiO1stcfIeF9","https://ap.wps.com/l/cbCaiiO1stcfIeF9","pdf",539071,"English","# Study design and participants\n## Outcomes: relapse and brain structure\n# Olanzapine exposure metrics\n## Dosage associations\n## Steady state concentration associations\n# Key findings and interpretation\n## Therapeutic-range implications\n## Limitations and further research","[{\"question\":\"What clinical question did the study address regarding olanzapine?\",\"answer\":\"The study examined whether olanzapine exposure is associated with relapse and with changes in brain structure in patients with major depressive disorder with psychotic features.\"},{\"question\":\"What trial data were analyzed in STOP-PD II?\",\"answer\":\"Analyses used data from the Study of the Pharmacotherapy of Psychotic Depression II, a randomized placebo-controlled trial involving patients who reached remission on sertraline and olanzapine and were then randomized to continue sertraline plus olanzapine or switch to placebo for 36 weeks.\"},{\"question\":\"Were associations between olanzapine exposure and outcomes still significant for all patients?\",\"answer\":\"Associations related to relapse or cortical thickness were no longer significant when analysis was restricted to participants treated with olanzapine, and the findings suggest effects within the therapeutic range did not depend on dosage or steady state concentration.\"}]","Psychotic Depression II Trial Olanzapine Exposure Relapse and Brain Structure Findings | PDF",48]